86Y-DOTA0-d-Phe1-Tyr3-octreotide (SMT487)—a phase 1 clinical study: pharmacokinetics, biodistribution and renal protective effect of different regimens of amino acid co-infusion

@article{Jamar200386YDOTA0dPhe1Tyr3octreotideP,
  title={86Y-DOTA0-d-Phe1-Tyr3-octreotide (SMT487)—a phase 1 clinical study: pharmacokinetics, biodistribution and renal protective effect of different regimens of amino acid co-infusion},
  author={François Jamar and Raffaella Barone and Isabelle Mathieu and St{\'e}phan Walrand and Daniel Labar and Pascal Carlier and Jo{\"e}lle De Camps and Horst F Schran and Tianling Chen and Michael C. Smith and Hakim Bouterfa and Roelf Valkema and Eric P. Krenning and Larry K. Kvols and Stanislas P. Pauwels},
  journal={European Journal of Nuclear Medicine and Molecular Imaging},
  year={2003},
  volume={30},
  pages={510-518}
}
The pharmacokinetics and dosimetry of 86Y-DOTA0-d-Phe1-Tyr3-octreotide (86Y-SMT487) were evaluated in a phase I positron emission tomography (PET) study of 24 patients with somatostatin receptor-positive neuroendocrine tumours. The effect of amino acid (AA) co-infusion on renal and tumour uptake was assessed in a cross-over randomised setting. Five regimens were tested: no infusion, 4-h infusion of 120 g mixed AA (26.4 g l-lysine + l-arginine), 4 h l-lysine (50 g), 10 h 240 g mixed AA (52.8 g… CONTINUE READING
56 Citations
30 References
Similar Papers

Citations

Publications citing this paper.
Showing 1-10 of 56 extracted citations

References

Publications referenced by this paper.
Showing 1-10 of 30 references

Phase I study of peptide receptor radionuclide therapy with [In-DTPA]octreotide: the Rotterdam experience

  • R Valkema, M De Jong, +11 authors EP. Krenning
  • Semin Nucl Med
  • 2002
1 Excerpt

Effect of peptide amount on biodistribution of 86 Y - DOTA - Tyr 3 - octreotide ( SMT 487 )

  • P Jonard, F Jamar, +6 authors S Pauwels
  • J Nucl Med
  • 2000

Similar Papers

Loading similar papers…